Coherus BioSciences

 – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the…

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in the US; if approved, toripalimab will…

<!-- Name:DistributionId Value:8747614 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless of PD-L1 expression – …

– CIMERLI™ BLA review progressing toward August 2022 action date –– Toripalimab BLA resubmission expected by mid-summer –– UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million –– 2022 R&D and SG&A expense guidance reduced…

The Food and Drug Administration rejected two proposed new cancer drugs that were developed in China, underscoring a tougher U.S. regulatory stance toward such drugs.Hong Kong-based Hutchmed Ltd. said Monday…

REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today…

— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2 billion in annual net sales from Coherus' …

REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City. Coherus…

– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as…